Galderma Premieres Positive Interim Results Demonstrating the Efficacy of Its Injectable Aesthetics Portfolio in Addressing Facial Volume Loss as a Result of Medication-driven Weight Loss
Galderma (SWX:GALD) announces positive first results from a trial designed to explore the benefits of Restylane® Lyft™ or Contour™ in combination with Sculptra® in patients with medication-driven weight loss with associated facial volume loss.1 Initial three-month interim data from this first-of-its-kind trial suggest that this treatment combination effectively improved facial aesthetic appearance with high patient satisfaction.1 The results will be presented later today at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California.
Rates of medication-driven weight loss have increased rapidly in recent years and can be associated with facial alterations of variable magnitude.2-4 Patients can find that their skin is less radiant, drier or saggy, and can also observe changes in their facial structure and balance.3,4 Some even find that they appear older than their age.3,4 There are several reasons for these facial alterations including loss of fat, collagen, elastin and essential nutrients such as fatty acids.4
“We initiated this trial because we have the unique expertise, capability, and products needed to rapidly respond to the evolving needs of patients and healthcare professionals. It is encouraging to see these early results, which demonstrate the potential of our existing Injectable Aesthetics portfolio in addressing the effects of medication-driven weight loss on the skin, and we’re looking forward to presenting the nine-month data in due course.” FLEMMING ØRNSKOV, M.D., MPH
|
Three-month interim data provide response to one of the most predominant aesthetic concerns of patients taking prescription weight loss medicines
In a phase IV clinical trial conducted in the U.S., Galderma investigated the efficacy, safety, and patient satisfaction of Restylane Lyft™ or Contour™ in combination with Sculptra for cheek augmentation and correction of contour deficiencies in patients with medication-driven weight loss with associated facial volume loss.1 Informed by insights gained from pivotal trials of Sculptra and the Restylane portfolio, the trial took place across two sites and used the SHAPE Up Holistic Individualized Treatment (HIT™) as a treatment methodology.1 HIT™ is an individualized treatment approach which enables injectors to leverage their expertise with the renowned Galderma Restylane portfolio to optimize aesthetic outcomes while prioritizing patient satisfaction.
Patients were treated with Sculptra and either Restylane Lyft™ or Contour™ for their first treatment, a second treatment of Sculptra with an optional touch-up of Restylane Lyft™ or Contour™ at Week 4, and an optional third treatment of Sculptra at Week 8.1 Follow-up visits took place at Week 20 for those who received the third Sculptra treatment and at Week 16 for those who did not, corresponding to three months after their final treatment.1
Results at three months demonstrated that the combination of Sculptra and Restylane Lyft™ or Contour™ effectively improved the facial aesthetic appearance of patients experiencing significant medication-driven weight loss with associated facial volume loss, further supporting the benefits of the SHAPE Up HIT™:1
- Three months after their final treatment, subjects showed improved mid-face shape and contouring along with improvements in cheek wrinkles and an overall improvement in facial appearance1
-
Skin quality findings, which were assessed and reported in the Sculptra/Restylane Lyft™ regimen, demonstrated improvements beyond visual improvement; with Sculptra significantly improving skin radiance and skin thickness three months after final injection treatment1
- Additionally, results showed Restylane Lyft™ significantly improved skin hydration as early as Week 4, which was maintained at the three-month follow-up visit1
-
Subjects reported high satisfaction as early as four weeks after their first treatment session, which was maintained through to three months after their treatment1
- At Week 4, 85% said their face looked more refreshed, and almost 80% noticed their facial balance was improved, and said the SHAPE Up HIT™ enhanced their face’s structural harmony1
- 89% felt more attractive and happier with their appearance and agreed it provided natural looking results at three months post follow-up1
Safety was in line with previous pivotal trial data for all products, with no treatment-related adverse events reports.1
“As medication-driven weight loss becomes more prolific around the world, so do the associated impacts of facial volume loss and other unwanted cosmetic effects like shadowing and hollowness. This innovative study is going to be invaluable in exploring how best to address these facial alterations, with results so far being very promising.” MICHAEL SOMENEK, MD
|
Galderma’s broad portfolio addresses key patient and healthcare professional needs
Galderma is well-positioned to address these alterations, given its expertise and experience in dermatology, specialized range of injectable treatments and skincare products, and its patient-centric approach, developed in close collaboration with leading healthcare professionals. While Sculptra - the first proven regenerative biostimulator with a unique poly-L-lactic acid (PLLA-SCA™) formulation - can help to restore skin integrity, our portfolio of Restylane hyaluronic acid injectables can help refine areas of the face that may have been altered during the weight loss journey.1,5-9
A six-month extension is now ongoing to confirm the long-term effects, a full nine months after final Sculptra treatment, to further confirm the benefits of the combination approach.
About the study
This phase IV trial was a multi-center, open-label study to evaluate the synergistic effects of Restylane® Lyft™ or Contour™ in combination with Sculptra® for cheek augmentation and correction of contour deficiencies, in patients experiencing facial volume loss following treatment with one of four brands of glucagon-like peptide-1 (GLP-1) receptor agonists.1 Conducted in the U.S., the trial took place across two sites, and used the SHAPE Up Holistic Individualized Treatment (HIT™) as a treatment methodology, with patients treated with Sculptra and either Restylane Lyft™ or Contour™ for their first treatment, a second treatment of Sculptra with an optional touch-up of Restylane Lyft™ or Contour™ at Week 4, and an optional third treatment of Sculptra at Week 8.1 Follow-up visits took place at Week 20 for those who received the third Sculptra treatment and at Week 16 for those who did not.1 Skin quality findings were assessed in the Sculptra/Restylane Lyft™ regimen.1
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
References
- Galderma. Data on file. Somenek M and Lorenc P. A multi-center, open-label study to evaluate the synergistic effects of biostimulator and dermal fillers for cheek augmentation and correction of contour deficiencies.
- Mansour MR, et al. The rise of “Ozempic Face”: Analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP-1 agonists. JPRAS. 2024;96:225-227. doi: 10.1016/j.bjps.2024.07.051
- Tay JQ. Ozempic face: A new challenge for facial plastic surgeons. JPRAS. 2023;81:97-98. doi: 10.1016/j.bjps.2023.04.057
- Humphrey CD and Lawrence AC. Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg. 2023;39:719-721
- Sculptra®. EU Instructions for Use. 2021. Available online. Accessed January 2025
- Widgerow A, et al. A randomized, comparative study describing the gene signatures of Poly-L-Lactic Acid (PLLA-SCA) and Calcium Hydroxylapaptite (CaHA) in the treatment of nasolabial folds. Poster presented at IMCAS World Congress, February 1-3, 2024, Paris, France
- Galderma. Data on File (MA-60875)
- Zhang Y, et al. In vivo inducing collagen regeneration of biodegradable polymer microspheres. Regen Biomater. 2021;8(5):rbab042. doi: 10.1093/rb/rbab042
- Huth S, et al. Molecular Insights into the effects of PLLA_SCA on Gene Expression. J Drugs Dermatol. 2024;23(4):285-288. doi: 10.36849/JDD.779
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113255472/en/
Contacts
For further information:
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50
Sébastien Cros
Corporate Communications Director
sebastien.cros@galderma.com
+41 79 529 59 85
Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12
Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Duravant to Acquire Pattyn, Provider of Packaging Automation Systems for Bulk and Industrial Applications7.2.2025 15:00:00 CET | Press Release
Duravant LLC (“Duravant”), a global engineered equipment and automation solutions provider to the food processing, packaging and material handling sectors, announced today that it has entered into a definitive agreement to acquire the Pattyn Group BV (‘Pattyn”), a designer and manufacturer of automation systems specializing in B2B packaging. Pattyn is recognized as the premier leader for delivering comprehensive automation solutions and value-added services for bag-in-box packaging applications. Headquartered in Bruges, Belgium, Pattyn has over 70 years of expertise in machinery design and turnkey systems for counting, weighing, filling, and packing technologies for food, ingredients, and various non-food sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250207117623/en/ “We are extremely excited to partner with Pattyn,” said Mike Kachmer, Chairman and CEO of Duravant. “Pattyn has a rich history delivering high quality
Leclanché and Pinnacle Advance Strategic Partnership – Milestone Reached with Successful Completion of Due Diligence7.2.2025 09:50:00 CET | Press Release
Ad hoc announcement pursuant to Art. 53 LR Leclanché SA (SIX: LECN), a global leader in energy storage solutions, specialised in heavy duty batteries for Marine and Rail customers, is pleased to announce that Pinnacle International Capital Limited has completed the legal, financial and technical due diligence of the Leclanché group to its satisfaction, thereby fulfilling a key condition on the way to the implementation of the strategic partnership. As a next step in the transaction, Pinnacle will conduct an engineering review. The engineering review aims to optimise the agreed business plan and investment. At the same time, Leclanché will be working through an agreed workplan to address the due diligence items that were identified, with the goal of improving the starting point for the strategic partnership and the investment by Pinnacle. Through this transformative strategic partnership, Pinnacle’s investment will help unlock the strategic growth funding required to support Leclanché’s
Salience Labs Closed Series A Round Led by Applied Ventures and ICM HPQC Fund7.2.2025 09:14:00 CET | Press Release
Salience Labs Limited, a leader in photonic solutions targeting connectivity for AI datacenter infrastructure, today announced the successful close of $30 million in Series A financing led by ICM HPQC Fund and Applied Ventures, LLC, the venture capital arm of Applied Materials, Inc., to further the development of its optical switches for large scale AI connectivity. Applied Ventures and ICM HPQC Fund are joined by Strategic Investment Fund, Braavos, and continued participation from existing investors Oxford Sciences Enterprises, Cambridge Innovation Capital, and leaders from the global semiconductor industry including Silicon Catalyst and Jalal Bagherli. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250207290130/en/ Image by Shabbir Bashar “What our customers want is a photonic switch to connect their AI clusters that is compatible with existing infrastructure while delivering high bandwidth, low latency and significant pow
Japan Sake and Shochu Makers Association Announces 2024 Sake Export Data: Record-High Exports to 80 Countries, Up 6% YoY7.2.2025 04:00:00 CET | Press Release
2024 Sake Export Performance This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250205320328/en/ More people around the world are enjoying Japanese sake (Photo: Business Wire) The Japan Sake and Shochu Makers Association (JSS) has released 2024 sake export data. The total export value reached JPY 43.5 billion, a +6% increase from the previous year, with 3.45 million cases (9L equivalent) shipped to a record 80 countries. Since 2020, export value has grown 1.8 times, the average unit price increased 1.3 times, and the number of export destinations expanded by 19. Premium sake markets have seen significant growth in the past five years. Regionally, Asia accounted for 61% of total export value but saw a slight decline YoY. However, South Korea recorded a notable 29% growth, while Thailand and Malaysia also performed well. North America saw a 27% increase, driven by fine-dining adoption. Western Europe grew 18% YoY, expanding 2.5 ti
DNIB.com Reports Internet Has 364.3 Million Domain Name Registrations at the End of the Fourth Quarter of 20246.2.2025 23:19:00 CET | Press Release
VeriSign, Inc. (NASDAQ: VRSN), a global provider of critical internet infrastructure and domain name registry services, today announced that, according to the latest Domain Name Industry Brief Quarterly Report from DNIB.com, the fourth quarter of 2024 closed with 364.3 million domain name registrations across all top-level domains (TLDs), an increase of 2.0 million domain name registrations, or 0.5% compared to the third quarter of 2024. Domain name registrations also increased by 4.4 million, or 1.2%, year over year. The .com and .net TLDs had a combined total of 169.0 million domain name registrations in the domain name base at the end of fourth quarter of 2024, a decrease of 0.5 million domain name registrations, or 0.3% compared to the third quarter of 2024. The .com and .net TLDs had a combined decrease of 3.7 million domain name registrations, or 2.1%, year over year. As of Dec. 31, 2024, the .com domain name base totaled 156.3 million domain name registrations and the .net domai
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom